A Phase 1 interventional study of Lanabecestat and Iohexol in Renal Insufficiency, sponsored by Eli Lilly and Company. Withdrawn at 3 sites in United States. Open to participants aged 35 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-28.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
The purpose of the study is to determine whether lanabecestat can be safely prescribed in participants with kidney impairment without a dose adjustment.
Participants will be on study for up to 6 weeks; this includes a 2-week screening and a follow-up about 10 days after final drug administration.
1,995 studies on the registry are indexed under Renal Insufficiency; 173 are open to participants now.
Browse Renal Insufficiency studies →Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.
Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Lanabecestat administered orally to participants with normal renal function
Drug: Lanabecestat
Lanabecestat administered orally to participants with severe renal impairment, not on dialysis
Drug: Lanabecestat · Drug: Iohexol
Administered orally
Also known as: LY3314814
Administered intravenously. Administration is at investigator's discretion in participants with severe renal impairment.
Pharmacokinetics (PK): Area Under The Concentration Versus Time Curve From Zero To Infinity (AUC[0-∞]) for Lanabecestat
PK: AUC(0-∞) for Lanabecestat
Time frame: Baseline through 168 hours after the administration of study drug
PK: Maximum Observed Drug Concentration (Cmax) of Lanabecestat
PK: Cmax of Lanabecestat
Time frame: Baseline through 168 hours after the administration of study drug
This study is withdrawn, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company